N. Bahlis

Minimal residual disease (MRD) assessment by flow cytometry after ASCT for AL amyloidosis: are we there yet?

P. Neri, H. Lee, P. Duggan, 2017, Bone Marrow Transplantation.

Autologous transplantation for primary systemic AL amyloidosis is feasible outside a major amyloidosis referral centre: the Calgary BMT Program experience

L. Chow, N. Bahlis, D. Stewart, 2005, Bone Marrow Transplantation.

Multiple myeloma-associated AL amyloidosis: is a distinctive therapeutic approach warranted?

H. Lazarus, N. Bahlis, N. Bahlis, 2006, Bone Marrow Transplantation.

Allogeneic transplantation for adult acute leukemia in first and second remission with a novel regimen incorporating daily intravenous busulfan, fludarabine, 400 CGY total-body irradiation, and thymoglobulin.

J. Storek, N. Bahlis, N. Bahlis, 2007, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Transplantation from matched siblings using once-daily intravenous busulfan/fludarabine with thymoglobulin: a myeloablative regimen with low nonrelapse mortality in all but older patients with high-risk disease.

J. Storek, P. Duggan, N. Bahlis, 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Transplantation from matched siblings using once-daily intravenous busulfan/fludarabine with thymoglobulin: a myeloablative regimen with low nonrelapse mortality in all but older patients with high-risk disease.

J. Storek, P. Duggan, N. Bahlis, 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

High busulfan exposure is associated with worse outcomes in a daily i.v. busulfan and fludarabine allogeneic transplant regimen.

B. Andersson, F. Naveed, J. Storek, 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Outcomes following HSCT using fludarabine, busulfan, and thymoglobulin: a matched comparison to allogeneic transplants conditioned with busulfan and cyclophosphamide.

M. Horowitz, K. Ballen, C. Bredeson, 2008, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

The addition of 400 cGY total body irradiation to a regimen incorporating once-daily intravenous busulfan, fludarabine, and antithymocyte globulin reduces relapse without affecting nonrelapse mortality in acute myelogenous leukemia.

W. Irish, C. Brown, J. Storek, 2010, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

Development and validation of a test dose strategy for once-daily i.v. busulfan: importance of fixed infusion rate dosing.

A. Magliocco, F. Naveed, J. Storek, 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.